Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Recruiting

Phase 1

Phase 2

AlpeliSib & PEmbroLizumabPhase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06545682

Conditions

Myelodysplastic Syndrome(MDS)

Acute Myelogenous Leukemia (AML)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Alpelisib + Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-03-17.